» Articles » PMID: 17261111

A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases

Overview
Journal Value Health
Publisher Elsevier
Date 2007 Jan 31
PMID 17261111
Citations 260
Authors
Affiliations
Soon will be listed here.
Abstract

The increasing number of retrospective database studies related to medication compliance and persistence (C&P), and the inherent variability within each, has created a need for improvement in the quality and consistency of medication C&P research. This article stems from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) efforts to develop a checklist of items that should be either included, or at least considered, when a retrospective database analysis of medication compliance or persistence is undertaken. This consensus document outlines a systematic approach to designing or reviewing retrospective database studies of medication C&P. Included in this article are discussions on data sources, measures of C&P, results reporting, and even conflict of interests. If followed, this checklist should improve the consistency and quality of C&P analyses, which in turn will help providers and payers understand the impact of C&P on health outcomes.

Citing Articles

Impact of the family doctor system on medication adherence among type 2 diabetes patients in China: a difference-in-differences analysis.

Tong X, Zou H, Zhang L, Chen W BMC Public Health. 2025; 25(1):404.

PMID: 39891108 PMC: 11786533. DOI: 10.1186/s12889-025-21656-0.


Despite the pandemic: upward trajectories of medication adherence and persistence in patients with dyslipidemia.

Jang J, Oh H, Lee E Front Pharmacol. 2024; 15:1488452.

PMID: 39712500 PMC: 11658976. DOI: 10.3389/fphar.2024.1488452.


Assessment of Phosphorodiamidate Morpholino Oligomer Treatment Patterns for Patients with Duchenne Muscular Dystrophy: A MarketScan Claims Analysis.

Klimchak A, Signorovitch J, Innis B, Laverty C, Gooch K Adv Ther. 2024; 42(1):523-536.

PMID: 39527337 PMC: 11782370. DOI: 10.1007/s12325-024-03044-z.


Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes.

Gronroos N, Swift C, Frazer M, Sargent A, Leszko M, Buysman E J Health Econ Outcomes Res. 2024; 11(2):118-124.

PMID: 39507603 PMC: 11539928. DOI: 10.36469/001c.124111.


Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia.

Zacker C, Puckett J, Kamal-Bahl S Clinicoecon Outcomes Res. 2024; 16:567-579.

PMID: 39161925 PMC: 11330860. DOI: 10.2147/CEOR.S469001.